RSPO1 Protein No Further a Mystery
All enrolled clients who received at least 1 dose of zosuquidar or placebo all through induction have been monitored for that prevalence of adverse occasions (439 sufferers, 219 on zosuquidar and 210 on placebo). The most common adverse situations were linked to the period of prolonged and significant myelosuppression as is anticipated with inducti